SCHEMBL2383176

SCHEMBL2383176

COc1ccc(COc2nsnc2N2CCN(C(=O)Nc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.54
▸ MAPT P10636 2/20 0.54
▸ HSD17B10 Q99714 3/20 0.52
▸ GAA P10253 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ CDK1 P06493 4/20 0.48
▸ IGF1R P08069 4/20 0.48
▸ FGFR1 P11362 4/20 0.48
▸ BRAF P15056 4/20 0.48
▸ FGFR2 P21802 4/20 0.48
▸ FGFR4 P22455 4/20 0.48
▸ FGFR3 P22607 4/20 0.48
▸ JAK1 P23458 4/20 0.48
▸ CDK2 P24941 4/20 0.48
▸ AXL P30530 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385756 0.90 MAPT (0.51) LMNAMAPTHSD17B10GAASMN1; SMN2
SCHEMBL2386074 0.89 MAPK10 (0.47) LMNAMAPTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL2382772 0.89 TRPV1 (0.49) HSD17B10NPSR1PDGFRBMAPK10TRPV1
SCHEMBL2386175 0.86 TRPV1 (0.47) MAPTALDH1A1NPSR1KDM4ETRPV1
SCHEMBL2385875 0.85 TRPV1 (0.44) LMNAMAPTSMN1; SMN2HTTPDGFRB
SCHEMBL2383198 0.85 TRPV1 (0.43) LMNAMAPTHSD17B10GAASMN1; SMN2
SCHEMBL2381535 0.85 TRPV1 (0.43) LMNAMAPTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL2382754 0.85 TRPV1 (0.45) LMNAMAPTHSD17B10SMN1; SMN2NPSR1
SCHEMBL2381536 0.85 TRPV1 (0.43) LMNAMAPTHSD17B10GAASMN1; SMN2
SCHEMBL2384046 0.84 TRPV1 (0.45) LMNAMAPTHSD17B10SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR LMNA 2968/4885MAPT 2716/4885HSD17B10 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback